BBIO vs. BPMC, TPTX, RETA, PRGO, BHVN, ALNY, TEVA, GMAB, RPRX, and BMRN
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Blueprint Medicines (BPMC), Turning Point Therapeutics (TPTX), Reata Pharmaceuticals (RETA), Perrigo (PRGO), Biohaven (BHVN), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
BridgeBio Pharma (NASDAQ:BBIO) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.
BridgeBio Pharma currently has a consensus price target of $47.62, indicating a potential upside of 71.09%. Blueprint Medicines has a consensus price target of $108.00, indicating a potential upside of 3.82%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Blueprint Medicines.
BridgeBio Pharma has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
99.9% of BridgeBio Pharma shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Blueprint Medicines has a net margin of -102.15% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Blueprint Medicines' return on equity.
In the previous week, BridgeBio Pharma had 9 more articles in the media than Blueprint Medicines. MarketBeat recorded 23 mentions for BridgeBio Pharma and 14 mentions for Blueprint Medicines. BridgeBio Pharma's average media sentiment score of 0.44 beat Blueprint Medicines' score of 0.36 indicating that BridgeBio Pharma is being referred to more favorably in the media.
Blueprint Medicines has higher revenue and earnings than BridgeBio Pharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines received 375 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 68.40% of users gave BridgeBio Pharma an outperform vote while only 67.89% of users gave Blueprint Medicines an outperform vote.
Summary
BridgeBio Pharma beats Blueprint Medicines on 12 of the 17 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
